A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 28
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LABAs
Long Form : long-acting beta2-adrenoceptor agonists
No. Year Title Co-occurring Abbreviation
2022 Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. GWAS, PheWAS, SNPs
2021 Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. COPD, ICSs, LAMAs, MDIs
2021 Inhaled β2 Adrenergic Agonists and Other cAMP-Elevating Agents: Therapeutics for Alveolar Injury and Acute Respiratory Disease Syndrome? ARDS, beta2-ARs
2020 Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19. ---
2020 Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. COPD, LAMAs
2019 Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis. COPD, PDE
2019 Pharmacology and Therapeutics of Bronchodilators Revisited. beta 2-ARs, COPD, LAMAs
2018 Long-Acting beta2-Adrenoceptor Agonists Enhance Glucocorticoid Receptor (GR)-Mediated Transcription by Gene-Specific Mechanisms Rather Than Generic Effects via GR. 2GRE, GR, ICSs, pHBECs
2018 Real-world Clinical Characteristics, Treatment Patterns, and Exacerbations in US Patients With Asthma Newly Treated With Omalizumab. ICSs
10  2017 Long-acting beta2-agonists promote glucocorticoid-mediated repression of NF-kappaB by enhancing expression of the feedback regulator TNFAIP3. ICSs, TNFAIP3
11  2017 Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation. GPCRs, HDM, ICSs, RGS2
12  2017 Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. ICSs
13  2016 How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? LAMAs
14  2016 [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle]. ---
15  2015 Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting beta2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. COPD, ICS
16  2014 A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study. FEV1, FVC, ICSs
17  2014 Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. ASM, BI, EFS, LAMAs
18  2014 Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting beta2-adrenoceptor agonist-induced gene expression in human airway epithelial cells. COPD, ICS, PDE
19  2014 Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. COPD, LAMAs
20  2013 Inflammatory cellular phenotypes and molecular mechanisms of glucocorticoid resistance in patients with bronchial asthma. GC, GCR, GR, HDAC, MAPK, PI3K, Th
21  2013 Reaching beyond disparity: safely improving asthma control in the at-risk African-American population. ---
22  2012 Characterization of long-acting beta₂-adrenergic agonists utilization in asthma patients. FDA, FDC, ICS, LTRAs, MCR, SI
23  2012 Increased corticosteroid sensitivity by a long acting beta2 agonist formoterol via beta2 adrenoceptor independent protein phosphatase 2A activation. DEX, GR, JNK, PP2A
24  2011 Roflumilast for COPD. COPD, COPD
25  2010 Innovations to achieve excellence in COPD diagnosis and treatment in primary care. COPD, FDA
26  2010 Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure. ASM, PDE4
27  2006 Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. CI, COPD, FEV1, PEF, RCTs
28  2005 Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. ---